Full-Time

Head of Vision Care Solutions

Director

Updated on 9/3/2026

Zeiss

Zeiss

1,001-5,000 employees

Corporate venture capital for deep-tech startups

No salary listed

Company Does Not Provide H1B Sponsorship

Kentucky, USA

Remote

Remote in Kentucky; must be eligible to work in the United States.

Bachelor's

Category
Business & Strategy
Required Skills
Risk Management

Get referred to Zeiss

See people who can refer or advise you

Requirements
  • Bachelor's degree
  • 10+ years of experience in technology solutions leadership, with at least 5 years in a senior management role
  • Minimum of 10 years relevant experience in Optical and Medical Device sales
  • Knowledge of Vision Care Solutions (VCS) and MED RDx devices and the eye care industry
  • Strong conceptual, analytical, and problem-solving ability
  • Credible and confident communicator (written and verbal) and first-class presentation skills
  • Experience in optical or vision care industry
  • Familiarity with global operations and multi-market strategies
  • Ability to lead digital transformation initiatives
  • Commercially astute, customer focused and “can-do” attitude
  • Ability to build strong external relationships to enhance and strengthen the VCS reputation
  • Strong leadership skills and experience
Responsibilities
  • Define and execute U.S. VCS strategy in alignment with global objectives
  • Identify market trends and opportunities to expand VCS offerings
  • Represent VCS in executive forums and contribute to long-term business planning
  • Ensure adherence to HIPAA, FDA, and Data Privacy regulations for all VCS products and services
  • Oversee quality assurance processes and risk management protocols
  • Lead integration efforts with PMS/EMR providers and other technology partners
  • Collaborate with R&D, supply chain, and commercial teams to deliver seamless solutions
  • Build and mentor a high-performing VCS team
  • Implement training and certification programs for technical sales and support staff
  • Ensure VCS team is kept fully trained and when necessary certified to sell, install and correctly service complete portfolio, in cooperation with sales and technical service management
  • Drive strategic account acquisition and retention
  • Support sales teams with executive-level presentations and solution positioning
  • Monitor KPIs and financial performance to ensure revenue and profitability targets are met
  • Organize all approved Trade Show activities to ensure maximum impact and return on investment
  • Follows safety standards and reports any safety concerns to leadership

ZEISS Ventures is the corporate venture capital arm of the ZEISS Group, investing in deep-tech startups in Information Technology, Industrial Tech, MedTech, and Life Sciences. It backs early-stage companies at pre-Series A to Series A with typical investments of $1–5 million. The fund provides capital and tailored funding solutions, leveraging ZEISS’s global network and optics/optoelectronics expertise to support portfolio companies. Its goal is to accelerate the development of new technologies and business models that complement ZEISS’s portfolio while actively engaging with external innovation.

Company Size

1,001-5,000

Company Stage

Growth Equity (Non-Venture Capital)

Total Funding

$67.7M

Headquarters

Oberkochen, Germany

Founded

2001

Get referred to Zeiss

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • ZEISS Ventures led SeeTrue's €2.2 million round on 2026-08-05, reinforcing eye-tracking leadership.
  • ZEISS backed Maculaser and Custom Surgical in 2026, deepening ophthalmology innovation pipelines.
  • ZEISS launched Otus ML 1.4/35, Panoptes 65, and DuraVision Plus in 2026.

What critics are saying

  • ZEISS Meditec plans up to 1,000 job cuts through 2028/29 after 5.7% revenue decline.
  • ProfitUp requires over €150m restructuring costs, signaling weak margins and execution strain.
  • If ophthalmology turnaround fails, ZEISS Meditec drags group cash flow and venture appetite.

What makes Zeiss unique

  • ZEISS Ventures backs deep-tech tied to ZEISS optics, medtech, and industrial workflows.
  • ZEISS brings distribution, engineering, and clinical validation to early startups like Custom Surgical.
  • ZEISS spans lenses, microscopy, and eye care, creating cross-selling across adjacent markets.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

401(k) Retirement Plan

Paid Vacation

Performance Bonus

Company News

Yahoo Finance
Aug 27th, 2026
ZEISS launches DORC EVA NEXUS cataract system at ESCRS in London

ZEISS Medical Technology has launched a cataract-only configuration of its DORC EVA NEXUS ophthalmic surgical system. The system features a cataract grade selection with up to four programmable presets, allowing surgeons to optimise phaco, aspiration, and irrigation settings for each surgical step. The solution includes VacuFlow VTi pump, SMART IOP, and EVA EQUIPHACO technologies, designed to provide streamlined performance, stability, and control during procedures. It integrates with the ZEISS Cataract Workflow portfolio. The system debuted at the European Society of Cataract and Refractive Surgeons congress in London. It will become available in select European countries from September 2026, with global rollout pending regulatory approvals. The technology expands ZEISS's existing EVA NEXUS platform, which previously focused on retina workflows.

PR Newswire
Aug 19th, 2026
ZEISS CLINIC 360 receives FDA clearance for cloud-based ophthalmic data management software

ZEISS Medical Technology announced FDA 510(k) clearance for ZEISS CLINIC 360, a cloud-based software solution that aggregates ophthalmic clinical data and provides advanced analytics. The browser-based platform combines diagnostic and medical data into a comprehensive patient view, helping clinicians evaluate disease progression and support treatment decisions. The solution integrates data from DICOM-enabled diagnostic devices, including ZEISS's CIRRUS, CLARUS and HFA systems, as well as third-party devices. It features disease-based summaries, interactive analysis tools, and collaboration capabilities through ZEISS Collaborative Care. ZEISS CLINIC 360 will be available in the US in early autumn 2026 on a subscription basis with low upfront costs. The platform complements ZEISS FORUM, the company's on-premise data management system, giving providers flexibility in choosing their preferred infrastructure approach.

ZEISS
Aug 5th, 2026
ZEISS leads $2.5M investment in SeeTrue Technologies for miniaturised eye-tracking tech

ZEISS Ventures led a €2.2 million investment round in SeeTrue Technologies, a Finnish deep-tech company developing miniaturised eye-tracking technology. The funding will accelerate commercialisation of SeeTrue's ultra-low-power eye-sensing architecture for next-generation interfaces in smart optical systems and eyewear. SeeTrue's proprietary technology combines miniaturised sensing hardware with optimised embedded processing, enabling scalable eye-sensing capabilities with low power consumption and small hardware footprint. The technology supports gaze-based interaction and attention-aware computing across healthcare, industrial, and smart eyewear applications. The investment round includes participation from Superhero Capital and North Karelia Growth Fund, managed by Redstone Nordics. Founded in 2018 and based in Joensuu, Finland, SeeTrue develops ultra-miniature eye-tracking technology for medical optical systems, vision care, and smart wearables.

PR Newswire
Jun 11th, 2026
ZEISS completes early implantations of AT LUCIA toric 721P intraocular lens

ZEISS Medical Technology has announced successful early clinical implantations of its AT LUCIA toric 721P intraocular lens, designed to treat cataracts whilst correcting astigmatism. The company is conducting an early-access clinical trial with experienced surgeons across six European countries. The lens combines an aspheric bitoric optic with a patented non-constant aberration design on a fully preloaded, hydrophobic platform. Surgeons have reported positive early impressions, highlighting the lens's precision, stability and surgical handling. Currently CE marked, the AT LUCIA toric 721P will be showcased at the International Congress of German Ophthalmic Surgery in Nuremberg from 18–20 June 2026. The lens is expected to be commercially available in select European countries later this year.

ZEISS
May 28th, 2026
ZEISS invests in Maculaser to advance temperature-controlled retinal laser therapy

ZEISS Ventures has invested in Maculaser, a Finnish medtech company developing temperature-controlled retinal laser therapy, through a funding round co-led with M2care. The investment will support clinical development of the company's personalized treatment for retinal diseases. Founded in 2020 and based on research from Aalto University, Maculaser has developed patented technology that provides real-time temperature control during laser treatment. The non-damaging approach activates natural cellular defence mechanisms, targeting affected retinal areas early to delay or prevent progression of age-related macular degeneration and diabetic maculopathy. The technology aims to shift retinal care from managing late-stage damage to proactive vision preservation, offering an outpatient procedure that integrates into regular eye care. Maculaser plans to bring the treatment into clinical practice to benefit millions of patients worldwide.